http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004105684-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09338f50511d9e40c2caa73805df5447 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b25a353e162fd7e0b3c6ed82a7ea2d30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ddc53c4c5d77422795daf0fc17742956 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faf0f68bc9b66c444a1b7b970ce248f7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2004-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd000b8085bc31f6358501b50fcdfc24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afd7b5c6b892903e4d72ddbbc08024a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f640e1d1f16ee2d982cf9665355b5381 |
| publicationDate | 2008-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2004105684-A3 |
| titleOfInvention | Combination therapy for proliferative disorders |
| abstract | The present invention provides methods of treating proliferative disorders, including angiogenesis-mediated disorders, cancer, and fibrotic disorders. In some embodiments, the methods involve administering a Type II interferon receptor agonist and a Type I interferon receptor agonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist, a stress-activated protein kinase (SAPK) inhibitor, and a third therapeutic agent. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a vascular endothelial growth factor (VEGF) antagonist. In other embodiments, the methods involve administering a VEGF antagonist and a SAPK inhibitor. The present invention further provides methods of treating fibrotic disorders. In some embodiments, the methods involve administering a Type I interferon receptor agonist, a Type II interferon receptor agonist; and a tumor necrosis factor (TNF) antagonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a TNF antagonist. In other embodiments, the methods involve administering pirfenidone or a pirfenidone analog and a TNF antagonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a transformining growth factor-beta (TGF-ß) antagonist. In other embodiments, the methods involve administering a SAPK inhibitor alone or in combination with a Type II interferon receptor agonist. In other embodiments, the methods involve administering N-acetyl cysteine (NAC) and a SAPK inhibitor. In other embodiments, the methods involve administering NAC and a Type II interferon receptor agonist. |
| priorityDate | 2003-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.